Artemisone - Artemis Therapeutics

Drug Profile

Artemisone - Artemis Therapeutics

Alternative Names: BAY-44-9585

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer; Medicines for Malaria Venture
  • Developer Artemis Therapeutics; Bayer; Hong Kong University of Science and Technology
  • Class Antimalarials
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria
  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 28 Nov 2017 Artemis Therapeutics has patent protection for Artemisone in European Union
  • 06 Nov 2017 Artemisone - Artemis Therapeutics receives Orphan Drug status for Malaria treatment in USA
  • 30 May 2017 Phase-I clinical trials in Malaria treatment in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top